{"title":"Trends and regional disparities in triptan dispensing in France between 2014 and 2025: A nationwide open-data study.","authors":"S Redon, V Arcani, A Donnet","doi":"10.1016/j.neurol.2026.08.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In France, triptans are currently the only reimbursed migraine-specific acute treatments. Previous French reimbursement-based studies have examined triptan use, healthcare burden, and prescribing preferences, but an integrated nationwide assessment of long-term dispensing trends has been lacking. We therefore aimed to assess nationwide trends in triptan dispensing, prescribing patterns, demographic characteristics, and regional disparities in France.</p><p><strong>Methods: </strong>We conducted a nationwide repeated cross-sectional study using OpenMedic, an open-access database derived from the French National Health Data System (SNDS). All reimbursed triptan dispensations identified using the ATC code N02CC were analyzed between 2014 and 2025. Annual dispensing indicators, demographic characteristics, prescriber categories, regional dispensing rates, and molecule-specific dispensing patterns were evaluated.</p><p><strong>Results: </strong>The annual number of dispensed triptan packages increased by 17.5% between 2014 and 2025 (4.1 to 4.8 million), whereas the number of treated patients remained relatively stable (969,927 to 949,639). Dispensing rates increased from 62.4 to 70.7 packages per 1000 inhabitants, while the mean number of dispensed packages per treated patient increased from 4.25 to 5.11. Reimbursement expenditures markedly decreased from €138.1 million to €66.7 million. Dispensing rates increased most markedly among individuals aged≥60 years. General practitioners remained the main prescribers, although the contribution of neurologists and hospital physicians progressively increased. Persistent regional disparities were observed across French regions.</p><p><strong>Conclusion: </strong>Triptan dispensing in France increased substantially between 2014 and 2025 despite stable numbers of treated patients. This evolution was mainly characterized by increasing dispensing intensity among treated patients, greater involvement of specialist prescribers, and persistent regional disparities.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue neurologique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurol.2026.08.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In France, triptans are currently the only reimbursed migraine-specific acute treatments. Previous French reimbursement-based studies have examined triptan use, healthcare burden, and prescribing preferences, but an integrated nationwide assessment of long-term dispensing trends has been lacking. We therefore aimed to assess nationwide trends in triptan dispensing, prescribing patterns, demographic characteristics, and regional disparities in France.
Methods: We conducted a nationwide repeated cross-sectional study using OpenMedic, an open-access database derived from the French National Health Data System (SNDS). All reimbursed triptan dispensations identified using the ATC code N02CC were analyzed between 2014 and 2025. Annual dispensing indicators, demographic characteristics, prescriber categories, regional dispensing rates, and molecule-specific dispensing patterns were evaluated.
Results: The annual number of dispensed triptan packages increased by 17.5% between 2014 and 2025 (4.1 to 4.8 million), whereas the number of treated patients remained relatively stable (969,927 to 949,639). Dispensing rates increased from 62.4 to 70.7 packages per 1000 inhabitants, while the mean number of dispensed packages per treated patient increased from 4.25 to 5.11. Reimbursement expenditures markedly decreased from €138.1 million to €66.7 million. Dispensing rates increased most markedly among individuals aged≥60 years. General practitioners remained the main prescribers, although the contribution of neurologists and hospital physicians progressively increased. Persistent regional disparities were observed across French regions.
Conclusion: Triptan dispensing in France increased substantially between 2014 and 2025 despite stable numbers of treated patients. This evolution was mainly characterized by increasing dispensing intensity among treated patients, greater involvement of specialist prescribers, and persistent regional disparities.
期刊介绍：
The first issue of the Revue Neurologique, featuring an original article by Jean-Martin Charcot, was published on February 28th, 1893. Six years later, the French Society of Neurology (SFN) adopted this journal as its official publication in the year of its foundation, 1899.
The Revue Neurologique was published throughout the 20th century without interruption and is indexed in all international databases (including Current Contents, Pubmed, Scopus). Ten annual issues provide original peer-reviewed clinical and research articles, and review articles giving up-to-date insights in all areas of neurology. The Revue Neurologique also publishes guidelines and recommendations.
The Revue Neurologique publishes original articles, brief reports, general reviews, editorials, and letters to the editor as well as correspondence concerning articles previously published in the journal in the correspondence column.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
